BJH - volume 11, issue 4, june 2020
B. Vandenhove PhD student, L. Canti PhD student, H. Schoemans MD, PhD, Y. Beguin MD, PhD, prof. F. Baron , E. Willems MD, PhD, C. Graux MD, PhD, T. Kerre MD, PhD, S. Servais MD, PhD
Acute graft-versus-host disease (aGVHD) remains a severe complication after allogeneic stem cell transplantation (alloHCT). It is a disregulated immune process, during which the immune cells of the donor attack the healthy tissues in the immunocompromised host. Over the past two decades, progress in understanding its pathophysiology have helped redefine aGVHD reactions and clinical presentations. Typically, the disease presents with serious inflammatory lesions mainly in the skin, gut and liver. Its severity is assessed by gathering clinical signs and dysfunctions of each organ. Despite standard prophylaxis regimens, aGVHD still occurs in approximately 30–60% of transplanted patients and remains a major cause of transplant-related morbidity and mortality. Hence, there is an urgent need for optimising preventive strategies. In this review, we give insights on how to make an accurate diagnosis and scoring assessment of aGVHD, propose a short overview of the current knowledge about its immunobiology and discuss the current and developing strategies for prevention.
(BELG J HEMATOL 2020;11(4):159–173)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
M. Pirotte MD, F. Forte , L. Lutteri , B. Otto , E. Willems MD, PhD, L. Belle , prof. F. Baron , Y. Beguin MD, PhD, P. Maquet , O. Bodard , S. Servais MD, PhD
BJH - volume 7, issue 6, december 2016
S. Servais MD, PhD, C. Grégoire MD, prof. F. Baron , E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD
Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.
(BELG J HEMATOL 2016;7(6):229–35)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
G. Ehx , M. Hannon , S. Humblet-Baron , S. Dubois , C. Daulne , P. Drion , E. Willems MD, PhD, S. Servais MD, PhD, Y. Beguin MD, PhD, prof. F. Baron
BJH - volume 6, issue Abstract Book BHS, january 2015
S. Servais MD, PhD, C. Menten PhD, Y. Beguin MD, PhD, C. Daulne , L. Delens , E. Willems MD, PhD, M. Hannon , prof. F. Baron
BJH - volume 6, issue Abstract Book BHS, january 2015
M. Hannon , S. Servais MD, PhD, R. Schots MD, PhD, E. Castermans , L. Seidel , A. Gothot MD, PhD, E. Baudoux MD, O. Giet PhD, N. Wanten , E. Willems MD, PhD, C. Daulne , I. Van Riet PhD, Y. Beguin MD, PhD, prof. F. Baron
BJH - volume 6, issue Abstract Book BHS, january 2015
A. Jaspers MD, PhD, prof. F. Baron , J. Maertens MD, PhD, B. De Prijck MD, R. Schots MD, PhD, C. Bonnet MD, K. Hafraoui , E. Willems MD, PhD, S. Servais MD, PhD, G. Fillet , Y. Beguin MD, PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
